Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

May 14, 2026 updated by: Ali Mohamed Ali ismail, Cairo University
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

hypthyroidism elder females (n=40) with glaucoma and fatty liver issues will randomly divided into group number 1 (n=20) that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month or group number II (n=20) that will receive levothyroxine only

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
    • Giza Governorate
      • Dokki, Giza Governorate, Egypt, 11432
        • Recruiting
        • Cairo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • subclinical hypothrodism (significant form)
  • primary opened angle gaulcoma in both eyes with ocular hypertension in both eyes )(high-tension typed glaucoma)
  • fatty liver (non alcholic type)
  • elder females

Exclusion Criteria:

  • respiratory issues
  • cardiac issues
  • renal issues

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group number 1
hypthyroidism elder females (n=20) with glaucoma and fatty liver issues recive their levothyroxine and physical activity program on treadmill thrice weekly for 6 month
Behavioral: physical activity
hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month
Active Comparator: group number 2
hypthyroidism elder females (n=20) with glaucoma and fatty liver issues will recive their levothyroxine only
Other: usual care
hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
intraocular pressure
Time Frame: 6 months
it will be assessed in both eyes
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
body mass index
Time Frame: 6 months
it will be assessed on empty stomach and bladder
6 months
waist circumfrence
Time Frame: 6 months
it will be assessed by tape at umblical level
6 months
systolic blood pressure
Time Frame: 6 months
it will be assessed by sphygmomanmometer
6 months
diastolic blood pressure
Time Frame: 6 months
it will be assessed by sphygmomanmometer
6 months
glaucoma assocaited life quality survey
Time Frame: 6 months
it is a questionaire evaluates life quality
6 months
triglyceridss
Time Frame: 6 months
it will be assessed in serum
6 months
high density lipoproteines
Time Frame: 6 months
it will be assesed in serum
6 months
alanine transamianses
Time Frame: 6 months
it will be assessed in serum
6 months
aspartate trasnamiansses
Time Frame: 6 months
it will be assessed in serum
6 months
physical conclusion of short form survey
Time Frame: 6 months
it will assess physical quality of lifes of females
6 months
Mental conclusion of short form survey
Time Frame: 6 months
it will assess physical quality of lifes of females
6 months
thyroid stimualting horomone
Time Frame: 6 months
it will be assessed in serum
6 months
fasting glycemia value
Time Frame: 6 months
it will be assessed in serum
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Principal Investigator: Ali MA Ismail, lecturer, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 15, 2026

Primary Completion (Estimated)

December 15, 2026

Study Completion (Estimated)

December 15, 2026

Study Registration Dates

First Submitted

May 9, 2026

First Submitted That Met QC Criteria

May 14, 2026

First Posted (Actual)

May 20, 2026

Study Record Updates

Last Update Posted (Actual)

May 20, 2026

Last Update Submitted That Met QC Criteria

May 14, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB000-14233-75

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Open Angle Glaucoma

Clinical Trials on physical activity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe